Pfizer Executive Summary

Financial Management: “The process for and the analysis of making financial decisions in the business context.” (Cornett, Adair, & Nofsinger, 2016, p. 5).

As shown in the financial income statement (Exhibit3), Intel Corp. (INTC) has a capital structure consisting most of equity. Intel has very little debt in its capital structure and the cost of debt would have only a marginal effect on the overall cost of capital. The current capital structure of Intel is not optimal yet since optimal capital structure is making minimum weighted-average cost of capital.

However, the Walgreens’ capital structure is similar to its stronger competitor CVS’ capital structure that I defined as the benchmark. CVS has a total liabilities and shareholders’ equity of $54,721.90, where total debt is $23,400 representing the 42.76% and total equity is $31,321.90 which represents 57.24%. Moreover, if we compare 2006 results to 2007, I realize that capital structure

Required Resources Brigham, E. F., & Ehrhardt, M. C. (2014). Financial management (14th ed.). Mason, OH: South-Western Cengage Learning.

We chose Johnson and Johnson as a company for our case analysis, and researches have shown that one of its main competitors is Pfizer, Inc.

What has been the financial performance of AstraZeneca over the last three years, and how does this compare to a company in the same industry?

The company operates four segments namely Pharmaceutical, Animal Health, Consumer Care, and Alliance segments (merck.com, 2012).

Pfizer operates with high and sustainable gross margin, above the industry average. Though there is a reduction in revenues in 2013 compared to 2012, whereas COGS stays almost at the same level. The main reason of revenue reduction is the loss of exclusivity of branded Lipitor, Geodon and other drugs (approximately $ 3.9 billion), whereas revenue growth from other

In studying Merck’s strength in the industry, we selected GlaxoSmithKline (GSK) and AstraZeneca (AZ), two established companies, as benchmarks to determine Merck’s competitiveness.

Merck is among the largest pharmaceutical organization found in the United States of America. It is ranked as one of the successful medical companies in the entire world. It plays a very significant role within the entire medical industry. It was founded in the year 1891 as a subset of the parent company located in Germany. During the year 1945, the company was incorporated as a full American company through the tutelage of the United States government. Its market coverage is broad in the area of offering pharmaceutical services. It is attributed to the high investment on research and development along with competent human resource on board.

Merck & Co., founded in 1891 as the United States subsidiary of the German company, Merck, is a pharmaceutical manufacturer headquartered out of Kenilworth, NJ. It employs approximately 68,000 people, and manufactures medications used in diabetes, infectious diseases, and oncology along with multiple kinds of vaccines. Merck & Co. (MRK) is a leader in the pharmaceutical industry. In studying MRK’s strength in the industry, we selected GlaxoSmithKline and AstraZeneca, two established companies, as benchmarks to determine MRK’s competitiveness. For the analysis, we will give a brief history of the companies. After the background, we will examine their FY2016 statements using key

The aim of this report is to analyse the financial position of Hikma Pharmaceutical PLC and GlaxoSmithKline PLC. The report will examine the firm’s daily operating activities and compares its performance with the closest competitor, the GlaxoSmithKline PLC. First, the report provides the industry overview and the background of both firms. Second, the report provides the segmented analysis in terms of products and geographical regions in order to better understand the performance of both firms. The report will then provide a financial ratio analysis of both firms in order to determine with certainty the best firm for investments The economic pressures including global crisis, price rise and increased rate of inflation and the general instability in the Eurozone affect both firms. The social, political and economic factors have a direct impact on the operating activities of both firms as well as their long-term growth decision plan. Finally After a careful examination of the financial ratios of both

In efforts to stop the bleeding Pfizer continued investments into research and development, acquisitions, engaging in cost-cutting programs to counteract losses from patent expiration and selling non-core assets. As well as focusing on its most promising late-stage drug candidates. Pfizer focused on partnerships to build its R&D activities, that including some collaborative activities with companies like Bristol-Myers Squibb-Pfizer to streamline operations at its research facilities with an overall goal of reducing its adjusted R&D spending to $6.5 billion and $7 billion, but unfortunately it didn’t work too well as in 2014 as research and development expenses topped the $8 billion mark.

In the first year it generated revenues of 67.8$ billion and net income of 8.26$ billion. (philippidis, 2011)Pfizer is the largest player in the pharmaceutical market having the best power in marketing and forming associations. It also posts the highest dividends in the industry. Pfizer faces challenges common to all pharmaceutical companies such as patent expiration and FDA regulation. It is dedicated to applying science and global resources to progress health and well-being at every stage of life. Subsidiary members are Agouron pharmaceuticals, G.D Searle & company, Greenstone, Park- Davis, Wyeth, Pharmacia, Upjohn, Warner &lambert. (control, 2011)

The industry was day to day increasing their products and also the values of good products providing increased during the October 2010, the Pfizer agreed to buy the King Pharmaceuticals because they need to make them self in the largest list of the companies they buy $3.6 billion in cash and $14.25 per share to the king industry: an approximately 60% premium of the overall King's closing the share prices of them in October 11, 2010. Pfizer develops the new things which are produces medicines and vaccines for the wide range of the medical disciplines, because they including the immunology, and oncology, with the cardiology, and neurology. Pfizer's all types of the products include blockbuster which use in drug